Literature DB >> 23199497

Public health issues of hepatitis C virus infection.

George Papatheodoridis1, Angelos Hatzakis.   

Abstract

Hepatitis C virus (HCV) is a leading cause of liver disease worldwide, as 130-170 million individuals are chronically infected and 350,000 patients die every year from HCV infection. The HCV prevalence varies widely among countries being highest in several African and Eastern Mediterranean countries. The incidence of new HCV infections may be declining in developed countries, but there is still a large reservoir of chronic infections. The most important mode of HCV transmission has been injecting drug use in developed countries with low prevalence and unsafe therapeutic injections in developing countries with moderate-high prevalence. Since there are no systematic screening policies, most patients remain undiagnosed. Even among diagnosed patients, a minority receives treatment due to several barriers to therapy. Given the high efficacy of treatment, public health authorities should recognise the importance of HCV and make resources available for the implementation of effective primary prevention, screening and management policies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23199497     DOI: 10.1016/j.bpg.2012.09.012

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  13 in total

Review 1.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 2.  Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches.

Authors:  Ester Badami; Rosalia Busà; Bruno Douradinha; Giovanna Russelli; Vitale Miceli; Alessia Gallo; Giovanni Zito; Pier Giulio Conaldi; Gioacchin Iannolo
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

3.  Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.

Authors:  Alena M Pfeil; Oliver Reich; Ines M Guerra; Sandrine Cure; Francesco Negro; Beat Müllhaupt; Daniel Lavanchy; Matthias Schwenkglenks
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

4.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2014-06-30

5.  Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.

Authors:  Kathryn J Snow; Jesse T Young; David B Preen; Nicholas G Lennox; Stuart A Kinner
Journal:  BMC Public Health       Date:  2014-08-11       Impact factor: 3.295

Review 6.  Thalassemias in South Asia: clinical lessons learnt from Bangladesh.

Authors:  Mohammad Sorowar Hossain; Enayetur Raheem; Tanvira Afroze Sultana; Shameema Ferdous; Nusrat Nahar; Sazia Islam; Mohammad Arifuzzaman; Mohammad Abdur Razzaque; Rabiul Alam; Sonia Aziz; Hazera Khatun; Abdur Rahim; Manzur Morshed
Journal:  Orphanet J Rare Dis       Date:  2017-05-18       Impact factor: 4.123

7.  Hepatitis C Infection Become a Common Issue Among Hemodialysis Patients in a Hemodialysis Center Jakarta, Indonesia, and Survival Comparison of Hemodialysis Patients with Hepatitis Infection between Two Hemodialysis Centers in Jakarta, Indonesia, and Penang, Malaysia.

Authors:  Diana Laila Ramatillah; Syed Azhar Syed Sulaiman; Amer Hayat Khan
Journal:  J Glob Infect Dis       Date:  2018 Apr-Jun

8.  The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges.

Authors:  M Behzadifar; S Azari; H A Gorji; M Martini; N L Bragazzi
Journal:  J Prev Med Hyg       Date:  2020-04-02

9.  Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population.

Authors:  Alexandra DeBose-Scarlett; Raymond Balise; Deukwoo Kwon; Susan Vadaparampil; Steven Xi Chen; Eugene R Schiff; Gladys Patricia Ayala; Emmanuel Thomas
Journal:  J Transl Med       Date:  2018-06-28       Impact factor: 5.531

10.  Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

Authors:  Harinder S Chahal; Elliot A Marseille; Jeffrey A Tice; Steve D Pearson; Daniel A Ollendorf; Rena K Fox; James G Kahn
Journal:  JAMA Intern Med       Date:  2016-01       Impact factor: 44.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.